Sounds good. Just so we know what we're each asserting...

Sounds good. Just so we know what we're each asserting where do you think we'll be?

I'm not quite prepared to accept their annualised figure so my base expectation for the half is:

Revenue $14m
Net cash above $3m (cash balance might be lower as I think they are paying back $250K/quarter)
Forecast for full year to be cashflow neutral
IKN and ALG growth to taper but numbers to still improve as smaller cohorts running off are replaced by the current crop.
No raise

I'm hoping for better but given they're investing in new roles and courses I'm a little worried they're inclined to spend every extra dollar they receive. If anything, I'm a little worried they'll have another bite at nursing or similar. I want profitability in this market, not growth.

Migration scaremongering will keep a lid on the share price but even that won't last if they're generating cash which (in my opinion) should come in 2025 with larger cohorts carrying over even if the 2025 intake is down.

All just my humble opinion.

What's your forecast Nostradamus?